ZA916098B - Oxazolidinodione derivatives - Google Patents

Oxazolidinodione derivatives

Info

Publication number
ZA916098B
ZA916098B ZA916098A ZA916098A ZA916098B ZA 916098 B ZA916098 B ZA 916098B ZA 916098 A ZA916098 A ZA 916098A ZA 916098 A ZA916098 A ZA 916098A ZA 916098 B ZA916098 B ZA 916098B
Authority
ZA
South Africa
Prior art keywords
oxazolidinodione
derivatives
oxazolidinodione derivatives
Prior art date
Application number
ZA916098A
Other languages
English (en)
Inventor
Richard Mark Hindley
Mark Hindley Richard
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of ZA916098B publication Critical patent/ZA916098B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA916098A 1990-08-06 1991-08-02 Oxazolidinodione derivatives ZA916098B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909017218A GB9017218D0 (en) 1990-08-06 1990-08-06 Novel compounds

Publications (1)

Publication Number Publication Date
ZA916098B true ZA916098B (en) 1992-09-30

Family

ID=10680236

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916098A ZA916098B (en) 1990-08-06 1991-08-02 Oxazolidinodione derivatives

Country Status (14)

Country Link
US (1) US5391565A (cg-RX-API-DMAC7.html)
EP (1) EP0542816A1 (cg-RX-API-DMAC7.html)
JP (1) JPH06500538A (cg-RX-API-DMAC7.html)
KR (1) KR930701434A (cg-RX-API-DMAC7.html)
AU (1) AU646491B2 (cg-RX-API-DMAC7.html)
CA (1) CA2093146A1 (cg-RX-API-DMAC7.html)
GB (1) GB9017218D0 (cg-RX-API-DMAC7.html)
IE (1) IE912772A1 (cg-RX-API-DMAC7.html)
MX (1) MX9100529A (cg-RX-API-DMAC7.html)
NZ (1) NZ239265A (cg-RX-API-DMAC7.html)
PT (1) PT98577A (cg-RX-API-DMAC7.html)
TW (1) TW199156B (cg-RX-API-DMAC7.html)
WO (1) WO1992002520A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA916098B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021166A1 (en) * 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
RU2134686C1 (ru) * 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
GB9225386D0 (en) * 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
TW268952B (cg-RX-API-DMAC7.html) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
US5614544A (en) * 1993-09-14 1997-03-25 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
GB9326171D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
DE69418311T2 (de) 1993-12-27 1999-11-04 Japan Tobacco Inc., Tokio/Tokyo Isoxazolidindionderivate und deren verwendung
TW363959B (en) * 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
RU2114844C1 (ru) * 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
TW403748B (en) 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
EP1006794B1 (en) 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
RU2196141C2 (ru) 1997-10-08 2003-01-10 Санкио Компани, Лимитед Замещенное конденсированное гетероциклическое соединение, способ фармакологического воздействия, способ ингибирования 5-липоксигеназы, ингибирования продукции липидных пероксидов или снижения уровня сахара в крови
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
AU6331199A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders
EP1124808A1 (en) * 1998-10-29 2001-08-22 Dr. Reddy's Research Foundation An improved process for the preparation of new antidiabetic agents
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
JP2003502369A (ja) 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
US6380191B1 (en) 1999-06-18 2002-04-30 Merck & Co. Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2002024689A1 (en) 2000-09-21 2002-03-28 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
HK1214760A1 (zh) 2012-11-05 2016-08-05 Commissariat à l'énergie atomique et aux énergies alternatives 用於消除体内血癌干细胞以及用於防止血癌复发的抗癌试剂如酪氨酸激酶和stat5拮抗剂优选为噻唑烷二酮的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents

Also Published As

Publication number Publication date
AU8317891A (en) 1992-03-02
JPH06500538A (ja) 1994-01-20
AU646491B2 (en) 1994-02-24
MX9100529A (es) 1992-04-01
IE912772A1 (en) 1992-02-12
GB9017218D0 (en) 1990-09-19
NZ239265A (en) 1994-02-25
WO1992002520A1 (en) 1992-02-20
TW199156B (cg-RX-API-DMAC7.html) 1993-02-01
PT98577A (pt) 1992-06-30
EP0542816A1 (en) 1993-05-26
KR930701434A (ko) 1993-06-11
US5391565A (en) 1995-02-21
CA2093146A1 (en) 1992-02-07

Similar Documents

Publication Publication Date Title
EP0440950A3 (en) Halogenallyl-azolyl derivatives
HU912356D0 (en) Rapacmycine derivatives
ZA916098B (en) Oxazolidinodione derivatives
EP0470466A3 (en) Halogenalkyl-azolyl derivatives
ZA914484B (en) Azolyl-propanol derivatives
ZA9172B (en) Azaoxindole derivatives
LTIP848A (en) Hiv-inhibiting benzene-acetamide derivatives
IL99576A0 (en) Triazacyclohexane derivatives
EP0438690A3 (en) Substituted pyrazolin derivatives
ZA914204B (en) Pyridinylpiperazine derivatives
ZA916254B (en) Halogenoalkyl-azolyl derivatives
EP0485984A3 (en) Diarylmethoxypiperidine derivatives
EP0520435A3 (en) Dc-89 derivatives
ZA915878B (en) Carboxymethylcyclopropane derivatives
OA09670A (en) Carbo-nucleoside derivatives
EP0440949A3 (en) Halogenallyl-azolyl derivatives
ZA914675B (en) 5-isothiazolamine derivatives
EP0453883A3 (en) 2-amino-4-trichloropyridine derivatives
GB2249094B (en) Hetero-imidazodiazepine derivatives
EP0449346A3 (en) 4-piperidinyl-ergoline derivatives
EG19362A (en) Azoaxindole derivatives
EG19474A (en) Nitroenamine derivatives
ZA912532B (en) Nitroenamine derivatives
IE901421L (en) Glucosaminyl-epi-podophyllotoxin derivatives
GB9008119D0 (en) Dehydro-oxathiazinone derivatives